1469P - The humanistic burden reported by patients with unresectable locally advanced or metastatic (adv/met) gastric cancer (GC), gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): An international real-world survey

Background

Patients with adv/met GC/GEJC/EAC have poor prognosis. To better inform healthcare decisions, this study examines the humanistic burden experienced by patients with adv/met GC/GEJC/EAC with respect to quality of life (QoL) and activities of daily living (ADL).

Methods

A cross-sectional study was administered in France, Germany, UK, US, Japan and China (April–October 2019). The humanistic burden in adv/met GC/GEJC/EAC patients, was assessed through physician-reported and patient-reported surveys. Patients completed the Functional Assessment of Cancer Therapy – Gastric Cancer (FACT-Ga), a 46-item instrument assessing patients’ QoL (range 0–184; higher scores indicating better QoL), the European Quality of Life–5 Dimension Questionnaire (EQ-5D-3L: utility scores range −0.59–1.00; VAS scores 0–100; higher scores indicating better health status) and questions on ADL impact, using a 7-point scale (7=extremely high impact).

Results

995 patients completed the survey. Patient median age was 66 years, 69% were male and mean time from initial diagnosis was 7 months. 87% were receiving active 1^st line systemic therapy and 13% receiving best supportive care only. The majority of patients were retired (59%) or on long-term sick leave (21%) and 66% required caregiver support (mean 31.3 total hours per week). 98% experienced symptoms (mean of 6.3 symptoms). Compared with US population norms for ages 65–74 (EQ-5D-3L: utility, 0.82; VAS, 75.1), patients reported poorer health utility and overall health (EQ-5D-3L: utility 0.69; VAS, 55.5). Patients also reported lower QoL (mean FACT-G, 57.5) compared with US population norms (FACT-G, 80.1). 46% of patients reported high impact (score 5–7) on ADL and 50% reported high impact on family/social life.

Conclusions

Patients with adv/met GC/GEJC/EAC experience a high impact on QoL and ability to perform ADLs with the majority not working and requiring caregiver support. This severe humanistic burden emphasizes the need for novel and more efficacious treatment approaches.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Adelphi Real World.

Funding

BMS.

Disclosure

J.P. Hall, K. Khela, R. Moon, C. Middleton-Dalby: Full/Part-time employment: Adelphi Real World who received funding from BMS for this analysis. D. Bertwistle: Shareholder/Stockholder/Stock options, Full/Part-time employment: BMS. H. Xiao: Shareholder/Stockholder/Stock options, Full/Part-time employment: BMS.